Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 9/20 | 0.52 |
| ▸ | AVPR2 | P30518 | 9/20 | 0.52 |
| ▸ | FFAR2 | O15552 | 4/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7109575 | 0.90 | AVPR2 (0.51) | AVPR1AAVPR2RAB9ASMN1; SMN2 | |
| SCHEMBL7107601 | 0.87 | AVPR1A (0.65) | AVPR1AAVPR2CDK4CCND1 | |
| SCHEMBL5836585 | 0.87 | AVPR2 (0.48) | AVPR1AAVPR2 | |
| SCHEMBL7115671 | 0.83 | AVPR2 (0.48) | AVPR1AAVPR2 | |
| SCHEMBL7114677 | 0.83 | AVPR2 (0.49) | AVPR1AAVPR2RAB9ASMN1; SMN2 | |
| SCHEMBL3537863 | 0.83 | AVPR1A (0.51) | AVPR1AAVPR2FFAR2 | |
| SCHEMBL5784180 | 0.81 | AVPR2 (0.54) | AVPR1AAVPR2CDK4CCND1 | |
| SCHEMBL5835280 | 0.81 | AVPR2 (0.46) | AVPR1AAVPR2SMN1; SMN2 | |
| SCHEMBL7107610 | 0.80 | PDE4A (0.46) | AVPR1AAVPR2 | |
| SCHEMBL3538425 | 0.80 | AVPR1A (0.76) | AVPR1AAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH | 2003-01-09 | — | — | US | claimed |
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | AVPR1A 62/4885AVPR2 91/4885FFAR2 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.